Traders Union
All News
Biopharma and rare disease therapies by Zevra Therapeutics

Advertiser Disclosure

Biopharma and rare disease therapies by Zevra Therapeutics

FDA Orange Book adds Zevra Therapeutics U.S. patent, extending rare disease treatment protection

Oleg Tkachenko
08.06.2026

FDA Orange Book adds Zevra Therapeutics U.S. patent, extending rare disease treatment protection

Zevra Therapeutics announced the FDA Orange Book listing of a U.S. patent that extends the company's exclusivity protection through November 2041. This move is aimed at advancing innovation for ...

Zevra Therapeutics CEO to present company updates at H.C. Wainwright BioConnect Investor Conference

Dmytro Kharkov
18.05.2026

Zevra Therapeutics CEO to present company updates at H.C. Wainwright BioConnect Investor Conference

Zevra Therapeutics has announced that its President and CEO, Neil McFarlane, will share the latest updates about the company during a fireside chat at the H.C. Wainwright BioConnect Investor ...

Zevra Therapeutics details arimoclomol and miglustat study findings for rare disease event

Elena Nikulina
17.05.2026

Zevra Therapeutics details arimoclomol and miglustat study findings for rare disease event

Zevra Therapeutics is set to present two encore posters at the SIMD2026 conference on May 18. The company will share results from the NPC002 clinical trial evaluating arimoclomol combined with ...

Zevra Therapeutics schedules first quarter 2026 results release and webcast for May 6

Olga Shendetskaya
22.04.2026

Zevra Therapeutics schedules first quarter 2026 results release and webcast for May 6

Zevra Therapeutics will announce its first quarter 2026 financial results and deliver a corporate update on Wednesday, May 6, 2026. The company has arranged a live webcast event at 4:30 p.m. ET, ...

Zevra Therapeutics to Engage Neurology Community at AANAM 2026 Booth in Chicago

Andrey Mastykin
16.04.2026

Zevra Therapeutics to Engage Neurology Community at AANAM 2026 Booth in Chicago

Zevra Therapeutics announced its participation at AANAM 2026, scheduled for April 18 to 22 in Chicago. The company invited the neurology community to visit its booth number 4834, where it will ...

Zevra Therapeutics partners with GeneDx to launch genetic testing for NPC in U.S.

Mikhail Vnuchkov
10.03.2026

Zevra Therapeutics partners with GeneDx to launch genetic testing for NPC in U.S.

Zevra Therapeutics has partnered with GeneDx to introduce a sponsored genetic testing program for eligible patients in the U.S. suspected of having Niemann-Pick disease type C (NPC). The ...

Zevra Therapeutics opens Nasdaq with bell ceremony

Dmytro Kharkov
10.02.2026

Zevra Therapeutics opens Nasdaq with bell ceremony

Zevra Therapeutics marked a significant milestone by participating in the opening bell ceremony at Nasdaq, highlighting an exceptional moment for their team. The presence at Nasdaq underscores ...

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.